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Functional Characterization of the HveA Homolog Specified by African Green Monkey Kidney
Cells with a Herpes Simplex Virus Expressing the Green Fluorescence Protein
Timothy P. Foster, Vladimir N. Chouljenko, and Konstantin G. Kousoulas 1
Department of Veterinary Microbiology and Parasitology, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 70803
Received November 23, 1998; returned to author for revision March 15, 1999; accepted April 5, 1999
We cloned the gene specified by African monkey kidney cells (Vero) that codes for the homolog of the herpes virus entry
mediator (HveA) specified by HeLa cells. The primary sequence of the monkey HveA (HveAs) differed significantly from
HveA. Single amino acid differences were distributed throughout the amino and carboxyl terminal portions of the HveAs in
comparison with the HveA, whereas certain regions were highly conserved. The predicted membrane spanning domains of
the two receptors differed substantially due to insertions and deletions of short amino acid sequences. The ability of HveAs
to mediate HSV virus entry was tested in a series of experiments using the recombinant virus KOS/EGFP, which constitutively
expressed the enhanced green fluorescence protein (EGFP) and Chinese hamster ovary cells (CHO) transformed with the
HveAs gene. The KOS/EGFP virus was constructed by inserting an EGFP gene cassette within the intergenic region between
the UL53 (gK) and UL54 (ICP27) genes. The KOS/EGFP virus formed viral plaques and replicated as well as the wild-type KOS
virus. HveAs-transformed CHO cells constitutively expressing HveAs mediated herpesvirus entry efficiently, whereas cells
transformed with the HveAs gene in the noncoding orientation did not mediate virus entry. A genetically engineered protein
composed of the amino-terminal portion of the HveAs protein fused to the heavy chain of mouse IgG immunoglobulin as well
as mouse antibodies raised against HveAs blocked virus entry into HveAs-transformed CHO cells. Thus, HveAs is the
functional homolog of HveA. © 1999 Academic Press

nuclear factor-kB (NF-kB), a transcriptional regulator of
multiple immunomodulatory and inflammatory genes as
well as activation of the Jun-containing transcription factor AP-1, a regulator of cellular stress-response genes.
These results suggest that HveA is associated with signal transduction pathways that activate the immune response (Marsters et al., 1997).
A second receptor for virus entry, HveB, is the poliovirus receptor-related protein 2 (Prr2). HveB mediates
HSV-2 but not wild-type HSV-1 viral entry (Eberle et al.,
1995). Apparently certain mutants of HSV-1 use HveB for
viral entry, and HveB but not HveA mediates pseudorabies virus entry. A third receptor, HveC, is the poliovirus
receptor-related protein 1 (Prr1), which is a human member of the immunoglobulin superfamily (Lopez et al.,
1995). HveC mediates entry of several alphaherpesviruses, including HSV-1 and -2, pseudorabies virus (PRV),
and bovine herpesvirus-1 (BHV-1). HveC is expressed in
human cells of epithelial and neuronal origin and is the
primary candidate for the coreceptor that mediates
HSV-1 and -2 viral entry into epithelial cells on mucosa
surfaces and virus spread to cells of the nervous system
(Geraghty et al., 1998). A fourth receptor, HveD, is the
poliovirus receptor Pvr (Mendelsohn et al., 1989). HveD
mediates the entry of PRV and BHV-1 but not of HSV-1
(Geraghty et al., 1998).
African green monkey kidney (Vero) cells are commonly used for the propagation of HSV-1 in many her-

INTRODUCTION
Early steps during productive infection of eukaryotic
cells by herpes simplex virus include initial binding of
virions to cell surfaces mediated by binding of viral
glycoproteins gB and gC onto glycosaminoglycan chains
that are ubiquitous on most cell surfaces (Spear, 1993).
Virion penetration into cells occurs via the pH-independent fusion of the viral envelope with the cell membrane
or an early endosome (Wittels and Spear, 1991) and is
mediated by at least viral glycoproteins gB, gD, and
gH-gL hetero-oligomers (Sarmiento et al., 1979; Cai et al.,
1988; Ligas and Johnson, 1988; Forrester et al., 1992;
Roop et al., 1993).
A gD receptor for virus entry, HveA, is an additional
member of the tumor necrosis factor receptor family
(Montgomery et al., 1996; Whitbeck et al., 1997; Geraghty
et al., 1998). HveA is expressed in various tissues, including liver, lung, kidney, spleen, and peripheral leucocytes, and it is the principal receptor for entry into human
lymphoid cells but not into other cell types (Montgomery
et al., 1996). The cytoplasmic region of HveA binds to
several members of the tumor necrosis factor-associated factor (TRAF) family, such as TRAF1, TRAF2, TRAF3,
and TRAF5 but not to TRAF6. Transient transfection of
HVEM (HveA) into human 293 cells causes activation of
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pesvirus laboratories as well as for the determination of
HSV-1 virus entry and egress. Therefore we cloned, sequenced, and characterized the Vero HveA homolog,
designated here as HveAs. Functional characterization
of HveAs for HSV-1 virus entry was accomplished
through the construction and use of a recombinant virus
constitutively expressing the enhanced green fluorescence protein (EGFP) while retaining wild-type KOS-like
characteristics. Our results indicate that HveAs is the
functional homolog of HveA.
RESULTS
Construction and genetic characterization of the
recombinant virus HSV-1 (KOS)/EGFP
Recently, we constructed the recombinant virus DgK/
EGFP expressing an engineered enhanced green fluorescent protein (EGFP) from a gene cassette inserted in
place of the glycoprotein K (gK) gene (Foster et al., 1999).
To facilitate our studies on HSV-1 entry, we engineered
the virus KOS/EGFP constitutively expressing EGFP by
inserting the HCMV-EGFP gene cassette into the intergenic region between the UL53 (gK) and the UL54
(ICP27) genes. First, plasmid pTF9202 was constructed
to contain the HCMV-EGFP cassette in the intergenic
region between the UL53 and UL54 genes. Next, the
deleted ICP27-UL54 region of the d27–1 viral genome
was rescued by plasmid pTF9202, while simultaneously
transferring the CMV-EGFP gene cassette into the viral
genome (Fig. 1). Similar methodologies were used to
construct the DgK virus (Jayachandra et al., 1997) and the
DgK/EGFP virus (Foster et al., 1999). Virus stocks from
marker-rescue experiments were collected, individual
virus plaques were plaque purified five times, and virus
isolates were tested by diagnostic PCR. Primer gKTr2 is
located within the deleted portion of the UL54 gene (Fig.
1c). Amplification with this primer is possible only if the
UL54 gene has been rescued by the pTF9202 plasmid.
Complementary DNA sequences to primer gKTr2 are
present in plasmid pTF9202 immediately upstream and
downstream of the CMV/EGFP gene cassette. (Figs. 1c
and 1d). Therefore amplification with primer pair
UL52KpnI2/gKTr2 generated two DNA fragments of 1569
and 3261 bp against KOS/EGFP viral DNA (Fig. 1e, lane
3), while only the 1569-bp DNA fragment was generated
against KOS viral DNA (Fig. 1e, lane 2). Primer pair
UL52KpnI2/CMVBamHI detected the presence of the
EGFP gene cassette within the KOS/EGFP viral genome
as evidenced by the PCR-amplified DNA fragment of
2401 bp (Fig. 1e, lane 5), whereas it did not produce a
PCR product against the KOS viral genome (Fig. 1e, lane
4). Additional PCR testing was performed to ensure that
the KOS/EGFP virus was not contaminated with the
d27–1 virus using primer pair UL52KpnI2/d27–1a (Fig.
1b). This primer pair produced the predicted size DNA
fragments of 3241 and 1613 bp against KOS and d27–1

viruses (Fig. 1e, lanes 6, and 8, respectively), and the
predicted DNA fragment of 4889 bp against the KOS/
EGFP virus (Fig. 1e, lane 7). A second DNA fragment of
650 bp was of nonspecific origin.
Plaque phenotype, EGFP expression, and growth
characteristics of the KOS/EGFP virus
The KOS/EGFP virus produced viral plaques similar in
appearance to those produced by the wild-type virus
KOS (Figs. 2a and 2c). Bright green fluorescence was
detected in all infected cells when viral plaques were
examined under the fluorescent microscope (Fig. 2b).
Fluorescence from Vero cells infected with either KOS or
KOS/EGFP viruses at an m.o.i. of 5 was detected using
FACS at 24 h p.i. Nearly, all KOS/EGFP-infected cells
emitted bright fluorescence, whereas KOS-infected cells
did not emit any fluorescence (Fig. 2d).
To determine the replication characteristics of the
KOS/EGFP virus, Vero cell monolayers were infected in
triplicates with either KOS or KOS/EGFP virus at a m.o.i.
of 10, and virus stocks were prepared at 12, 24, 36, and
48 h p.i. The KOS/EGFP virus replicated to high titers
approaching those of the KOS parental virus (Table 1).
Isolation of the gene coding for the Vero HveA
homolog (HveAs) and comparison of the HveA
and HveAs predicted amino acid sequences
Primers specific for the HveA gene were used to
isolate and clone the HveAs cDNA specified by Vero
cells. Translation of the largest open reading frame of the
HveAs cDNA sequence produced a putative protein of
283 amino acids sharing a high degree of homology with
the previously described HveA receptor gene (Montgomery et al., 1996). On the basis of the homology to HveA,
this protein was designated the HveA simian homolog
(HveAs). A comparison of the predicted amino acid sequences of HveA and HveAs is shown in Fig. 3. The two
proteins were of equal length (283 amino acids) but
contained a number of amino acid differences including
(i) 41 amino acid substitutions of which 24 were to similar
amino acids and 17 were to dissimilar amino acids. And
(ii) amino acid deletions and insertions principally located within the intramembrane sequences. Specifically,
HveAs contained a single amino acid insertion (aa 187 of
HveAs) and a single amino acid deletion (aa 212 of HveA)
and a segment of deleted amino acids (aa 216–218 of
HveA) and inserted amino acids (aa 216 and aa 222–226
of HveAs). Characteristically, the carboxyl terminus of
HveA contained three extra amino acids (P-N-H) in comparison with HveAs.
Functional characterization of the HveAs receptor
The ability of HveAs to mediate HSV-1 virus entry was
assessed through the use of HveAs-transformed CHO
cells, anti-HveAs antibody, and soluble HveA protein.
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FIG. 1. Construction of recombinant KOS and DgK viruses constitutively expressing the EGFP gene. (a) The top line represents the prototypic
arrangement of the HSV-1 genome indicating approximate map units. (b) The region of the mutant virus HSV-1 d27–1 genome containing the UL52,
UL53, and the partially deleted UL54 genes with relevant restriction endonuclease sites. (c) Plasmid pTF9201, which contains the CMV-IE-EGFP gene
cassette in place of the gK gene (Foster et al., 1999). (d) Plasmid pTF9202 was produced by inserting the gK gene within the unique KpnI/SpeI sites
of plasmid pTF9201. The approximate location of PCR primers, UL52KpnI2, gKTr2, and CMVBamHI are shown (b–d). (e) Diagnostic PCR of plaque
purified KOS/EGFP recombinant virus. DNA PCR products with the UL52KpnI2/gKTr2 primer pair (lanes 2 and 3) or the UL52KpnI2/CMVBamHI primer
pair (lanes 4 and 5) used to detect the EGFP gene. Lanes 6–8: PCR diagnostic with primer pair UL52KpnI2/d27–1a used to determine the purity of
viral stocks. Lanes 2, 4, and 6: KOS viral DNA. Lanes 3, 5, and 7: KOS/EGFP viral DNA. Lane 8: d27–1 viral DNA. Lane 1: lambda phage DNA digested
with HindIII (marker). Lane 9: 1-kb molecular weight ladder.

Anti-HveAs serum was produced by genetic immunization using plasmid pCMV/HveAs, and it was tested for its
ability to react with HveAs expressed in Escherichia coli
as a fusion protein with the maltose-binding protein
(MBP). Anti-HveAs serum reacted with a protein species
migrating with an apparent molecular mass of 70 kDa in
agreement with the expected apparent molecular mass

of electrophoretically separated MBP/HveAs fusion protein (Fig. 4a, lane 2 of immune samples). Anti-HveAs
serum did not react against MBP expressed in E. coli
(Fig. 4a, lane 1 of immune samples). Similarly, pre-immune sera did not react with either MBP or MBP/HveAs
proteins (Fig. 4a, lanes 1 and 2, respectively, of preimmune samples).
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FIG. 2. Morphology and fluorescence detection of KOS/EGFP viral plaques. Vero cells were infected with either KOS (c) or KOS/EGFP virus (a and
b) at an m.o.i. of 0.001 in 24-well plastic tissue culture plates. Individual viral plaques were photographed through the use of phase-contrast (a and
c) and epi-fluorescence (b) microscope under live conditions at 48 h p.i. FACS analysis of KOS- and KOS/EGFP-infected cells (m.o.i. of 5) was
performed at 48 h p.i. (d) as described previously (Foster et al., 1999).

Next, CHO cells were transformed with either pCMV/
HveAs or pCMV/sAevH. Plasmid pCMV/sAevH contains
the HveAs gene in the opposite (noncoding) orientation.
HveAs expression by CHO/HveAs and Vero cells was
assessed using anti-HveAs serum and FACS analysis.
TABLE 1
Viral yields of KOS and KOS/EGFP viruses
Titer (PFU/ml)
Virus

12 h p.i.

24 h p.i.

36 h p.i.

48 h p.i.

KOS
KOS-EGFP

5.0 3 10 7
3.0 3 10 7

1.5 3 10 8
1.0 3 10 8

2.0 3 10 8
1.4 3 10 8

2.0 3 10 8
1.5 3 10 8

Note. Subconfluent Vero cell monolayers (approximately 8 3 10 5
cells) were infected with each virus at an MOI of 5, and at 12, 24, 36,
and 48 h.p.i. the total number of infectious virions was determined. Viral
yields represent one of three experiments in which individual numbers
varied by less than 2-fold.

Anti-HveAs serum reacted strongly with paraformaldehyde-fixed Vero cells and CHO/HveAs cells (Figs. 4b and
4c, respectively, solid histograms). No background fluorescence was observed in control experiments in which
Vero cells were incubated with pre-immune sera prior to
incubation with goat-anti-mouse FITC-conjugate (Fig. 4b,
unfilled histogram). Anti-HveAs antibody did not react
with CHO/sAevH cells (Fig. 4c, unfilled histogram).
To facilitate virus entry blocking experiments, soluble
HveAs protein was produced by first, constructing a
gene cassette coding for the extracellular portion of
HveAs fused to the Fc portion of mouse IgG. Next CHO
cells were transformed with plasmid pCR/HveAs:Fc capable of constitutively expressing HveAs:Fc protein, and
HveAs:Fc protein was purified from supernatant fluids of
these cells using protein A sepharose beads (see Materials and Methods). The authenticity of HveAs:Fc protein was tested in immunoblots using anti-mouse-IgG
antibody. A protein species with an apparent molecular
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FIG. 3. Comparison of the amino acid sequences of the HveAs and HveAh. The HveAs (top lines) and HveA (bottom lines) amino acid sequences
were aligned through the use of computer-assisted algorithms and visual inspection. Both proteins are 283 amino acids long. Relevant structural
features of both proteins are marked as indicated.

mass of ;60 kDa was detected in immunoblots of electrophoretically separated HveAs:Fc protein (Fig. 5, lane
2), whereas anti-mouse IgG antibody did not react with

supernatants from CHO/sAevH control cells (Fig. 5, lane
1). The HveAs:Fc-purified protein was sensitive to digestion by PNGase F, indicating that it contained N-glycosy-
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FIG. 4. Detection of HveAs expression in E. coli, Vero, and HveAs-transformed CHO cells using anti-HveAs serum. (a) Immunoblot of electrophoretically separated HveAs/MBP fusion protein after expression in E. coli using anti-HveAs serum produced by genetic immunization. Pre-immune
and immune sera were tested as shown. Lanes labeled 1: MBP control. Lanes labeled 2: MBP/HveAs fusion protein. (b) Vero cells were analyzed
by FACS after reaction with either anti-HveAs antibody followed by reaction with anti-mouse-IgG labeled with fluorescein (filled histogram) or with
pre-immune sera as primary antibody (unfilled histogram). (c) CHO/HveAs (filled histograms)- and CHO/sAevH (unfilled histograms)-transformed cells
were analyzed by FACS to detect HveAs using anti-HveAs antibody.

lated carbohydrates (not shown). A glycosylated protein
with similar apparent mass was produced by a HveA:Fc
fusion protein (Montgomery et al., 1996)
Virus-entry experiments were performed by monitoring
EGFP expression specified by KOS/EGFP virus. KOS/

EGFP infection (m.o.i. of 5) of CHO/HveAs cells resulted
in most cells emitting green fluorescence at 24 h p.i.,
indicating successful viral entry (Fig. 6A). In contrast,
practically none of the KOS/EGFP-infected CHO/sAevH
control cells emitted fluorescence (Fig. 6B). Next experiments were performed using the soluble HveAs:Fc protein. Pre-incubation of KOS/EGFP virions with supernatant fluids from CHO/sAevH control cells did not reduce
the number of fluorescent cells, whereas pre-incubation
with purified HveAs:Fc protein reduced the number of
fluorescent cells substantially (Figs. 6C and 6D, respectively). Similarly, treatment of the CHO/HveAs cells with
pre-immune control serum prior to infection with KOS/
EGFP virus did not reduce the number of fluorescent
cells, whereas treatment with anti-HveAs antibody serum
caused a substantial decrease in the number of fluorescent cells (Figs. 6E and 6F, respectively).
DISCUSSION

FIG. 5. Immunoblot detection of HveA:Fc expression from CHO/
HveAs:Fc-transformed cells. Supernatants from either HveAs:Fc transformed CHO cells or naive CHO/sAevH control cells were subjected to
protein A sepharose purification and prepared for immunoblot analysis.
Immunoblots were reacted with goat-anti-mouse HRP reagent. Lane 1:
reaction with supernatant concentrate from CHO cells. Lane 2: reaction
with supernatant concentrate from HveAs:Fc-transformed CHO cells.

We report here the functional characterization of the
herpes simplex HveA receptor homolog specified by
African green monkey kidney cells, designated here as
HveAs. These studies were undertaken because Vero
cells constitute our primary cells in which virus entry and
egress are studied. Investigation of the ability of HveAs
to mediate HSV-1 virus entry was achieved through the
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EGFP was selected because this protein is capable of
emitting bright green fluorescence within cells in cell
culture under physiological conditions without the requirement of exogenous substances. In addition, EGFP
is highly stable under varying pH conditions, detergents
and reducing agents enabling the direct measurement of
EGFP accumulated expression (Chalfie et al., 1994;
Chalfie 1995). In this regard, EGFP detection provides a
useful alternative to b-galactosidase and other enzymes
because it does not require addition of toxic reagents
that inactivate cells and viruses.
The growth characteristics and plaque morphology of
the resultant KOS/EGFP virus were similar to wild-type
KOS virus, indicating that insertion of the EGFP gene
cassette between the two essential genes, UL52 and
UL54 as well as expression of the EGFP proteins did not
adversely affect virus replication. High levels of EGFP
expression were achieved in KOS/EGFP virus-infected
cells that was easily detected by fluorescence microscopy and quantified by FACS analysis. KOS/EGFP fluorescence was detected through the use of a fluorescent
microscope as early as 5–6 h p.i. and fluorescent
plaques were readily visualized at 12 h p.i. Fluorescence
emitted from cells located within the center of each
plaque increased with time, whereas newly recruited
cells appeared weakly fluorescent until EGFP accumulated at later times. This radial feature of fluorescence
emission enables an improved, time-dependent visualization of KOS/EGFP plaque formation in comparison
with phase-contrast microscopy.
FIG. 6. Blocking of virus entry by HveAs:Fc soluble protein and by
anti-HveAs antibodies. (A and C–F) CHO/HveAs cells infected with
KOS/EGFP virus at an m.o.i. of 10. (A) Untreated control. (B) CHO/sAevH
control cells (transformed with the HveAs gene in the noncoding
orientation). (C and D) CHO/HveAs cells were pre-treated with preimmune or anti-HveAs serum, respectively, for 30 min at room temperature prior to infection. (E and F) KOS/EGFP virus was pre-treated for 30
min at room temperature with CHO/sAevH control supernates and
soluble HveAs:Fc, respectively, for 30 min at 4°C prior to infections.

use of a novel wild-type KOS-like herpesvirus constitutively expressing the EGFP protein immediately after viral
entry into cells.
The KOS/EGFP virus
We inserted the EGFP gene cassette within the intergenic region between the UL53 and UL54 genes immediately after the poly-A sequence of the UL53 gene. The
purpose of this construction was to enable the monitoring of viral entry through the detection of EGFP fluorescence. In addition, EGFP could serve as a fluorescent
marker for the isolation of recombinant viruses containing gK mutations by simultaneously transferring mutated
gK genes and the EGFP gene cassette to viral genomes.

HveAs mediates HSV entry
The functionality of the HveA receptor was demonstrated principally by showing that CHO/HveA-transformed cells facilitated HSV-1 entry and that HSV-1 entry
into these cells was blocked by either soluble HveA:Fc
protein or anti-HveA antibodies (Montgomery et al.,
1996). We performed similar experiments with the exception that viral entry into cells was monitored through
fluorescence detection of the EGFP protein specified by
the KOS/EGFP virus. Collectively, these experiments
showed that HveAs mediates HSV virus entry in a specific manner. Undiluted amounts of anti-HveAs antibody
and CHO cell supernatants containing soluble HveAs:Fc
protein reduced viral entry into vero cells by ;40 and
20%, respectively, as measured by FACS (not shown).
The inability of anti-HveAs antibody and soluble
HveAs:Fc to fully inhibit virus entry into Vero cells is due
to either the use of the blocking reagents at nonsaturating conditions or the presence of the HveC and other
receptors on Vero cell surfaces (Geraghty et al., 1998).
The HveAs protein
Comparison of the cDNA-predicted amino acid sequences of HveA and HveAs proteins revealed conser-
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vation of all cysteine residues with the exception of a
single cysteine missing in the membrane-spanning portion of HveAs with respect to HveA. Furthermore overall
structural features, which identified the HveA protein as
a homolog to the TNF family of proteins, were conserved
(Montgomery et al., 1996). However, there was a significant divergence at the amino acid level between the
HveA and HveAs proteins. Most amino acid substitutions
were concentrated within specific regions of the amino
terminus of the molecule and were to similar amino
acids that are not expected to drastically alter the secondary structure of the molecule. However, certain
amino acid substitutions were to dissimilar amino acids,
which may alter structural properties of the protein.
These were: S9 to P9, R12 to W12, P14 to S14, T22 to R22,
S33 to P33, Q70 to L70, S79 to P79, T113 to R113, A115 to
E115, A140 to R140, S172 to P172, G182 to Q182, and
N183 to T183 in the extracellular portions of the proteins
and S233 to P230, I256 to T253, T258 to I254, and E276
to I273 in the cytoplasmic portions of the proteins. Significant insertions and deletions were noted in the predicted intramembranous sequences of the HveAs and
HveA proteins including a deletion that eliminated one
cysteine residue in the HveAs sequence in comparison
with the HveA sequence. However, both intramembranous sequences exhibited similar hydrophobic potential,
indicating that both proteins should be effectively anchored into membranes. The carboxyl terminus of HveA
ended in amino acids P-N-H, which were not present in
the carboxyl terminus of the HveAs protein. Deletion of
the terminal 26 amino acids of the HveA protein did not
adversely affect the ability of this protein to mediate
herpes simplex virus entry (Montgomery et al., 1996);
therefore the carboxyl terminal differences between
HveAs and HveA are not expected to significantly alter
the ability of HveAs to mediate HSV virus entry in comparison with HveA.
The primary sequences of gD specified by HSV and
simian herpes B virus (SHBV) are 58% identical. However, regions of gD that are important for HSV-1 virus
entry into Vero cells are highly conserved in HSV-1,
HSV-2, and SHBV (Bennett et al., 1992; Chiang et al.,
1994). Furthermore anti-HSV-1 gD monoclonal antibodies
that block HSV-1 binding to soluble HveA recognize
epitopes that overlap or are adjacent to these conserved
regions (Nicola et al., 1998). HSV enters into both HveA
and HveAs-transformed cells efficiently, suggesting that
conserved domains in the extracellular portions of HveA
and HveAs proteins may serve as common functional
sites for binding gD during viral entry.
MATERIALS AND METHODS
Cells and viruses
African green monkey kidney (Vero) cells were obtained from ATCC (Rockville, MD). Cells were propagated

and maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma Chemical Co., St. Louis, MO) containing
sodium bicarbonate and 15 mM HEPES, and supplemented with 7% heat inactivated fetal bovine serum
(FBS). V27 cells carry a stably integrated copy of the
HSV-1 (KOS) ICP27 gene and were kindly provided by Dr.
D. M. Knipe, Harvard Medical School. These cells were
cultured in DMEM supplemented with 7% FBS (Rice and
Knipe, 1990). HSV-1(KOS), the parental wild-type strain
used in this study, was originally obtained from Dr. P. A.
Schaffer (Dana-Faber Cancer Institute, Boston, MA).
HSV-1(KOS) d27–1, which has a 1.6-kb BamHI-StuI deletion of the ICP27 gene, also was kindly provided by Dr.
D. M. Knipe and was propagated in V27 cells (Rice and
Knipe, 1990).
Reagents
Restriction and DNA modification enzymes were obtained from New England BioLabs (Beverly, MA). RNase
and Proteinase K were purchased from Boehringer
Mannheim (Indianapolis, IN). Gel fragment purification
matrix and buffers (Prep-a-gene) were obtained from
BioRad (Hercules, CA). Sequencing grade [ 35S] dATP was
obtained from DuPont/NEN (Wilmington, DE). Amplitaq,
rTth XL Polymerase, and deoxynucleotide triphosphates
were purchased from Perkin–Elmer (Foster City, CA). All
synthetic oligonucleotide primers were synthesized by
the LSU Gene Probes and Expression Systems Laboratory ‘‘GeneLab’’ using phosphoamidite chemistry on an
Applied Biosystems ABI394 DNA/RNA synthesizer with
Perkin–Elmer (Foster City, CA) reagents.
Isolation of the HveAs gene and construction of
plasmids
Total RNA was extracted from Vero cells using TRIReagent (Molecular Research Center, Inc., Cincinnati, OH).
A cDNA library was constructed using Ready-To-Go YouPrime First-Strand Beads (Pharmacia Biotech Inc., Uppsala, Sweden). All PCR amplifications were performed
using the Gene-Amp PCR system 9600, AmpliTaq, and
other Perkin–Elmer reagents (Perkin–Elmer, Norwalk,
CT). PCR products were derived using HveA-specific
primers (Montgomery et al., 1996) and were cloned into
plasmid pCR2.1 using the TA-cloning kit (Invitrogen Inc.,
Carlsbad, CA) producing plasmid pCR/HveAs. The
cloned HveAs gene was sequenced using dideoxy-chain
termination methodology, and the predicted primary
structure of the protein was obtained (GenBank Accession No. AF147720). The HveAs gene was isolated from
plasmid pCR/HveAs after restriction with EcoRI and
cloned into plasmid pcDNA3.1Zeo 1 in the coding and
noncoding orientations producing plasmids pCMV/
HveAs and pCMV/sAevH, respectively. The extracellular
domain of HveAs (first 202 amino acids) was fused to a
DNA fragment specifying the Fc portion of the mouse IgG
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heavy chain using PCR-assisted splice-overlap-extension (Chouljenko et al., 1996) and cloned into plasmid
pCR3.1 using the eukaryotic TA-cloning kit (Invitrogen,
Inc.), producing plasmid pCR/HveAs:Fc. Also, this portion
of the HveAs gene was cloned into plasmid pMALc2
(NEB, Beverly, MA), producing plasmid pMAL/HveAs.
Plasmid pTF9202 was constructed by inserting the gK
gene, after amplification with primer pair UL52KpnI2/
gKSpeI (59-AACACCAACACTAGTGGTGGATGTCCTTATACC-39) into the unique KpnI and SpeI sites of
pTF9201 (Foster et al., 1999). This plasmid was used to
transfer the EGFP gene into the d27–1 viral genome.

Production of anti-HveAs-specific antibodies

Construction of the HSV-1 (KOS)/EGFP recombinant
virus

Production of HveA:Fc by CHO-transformed cells

Plasmid pTF9202 specifying the CMV-EGFP gene cassette flanked by homologous HSV-1 sequences was
transfected into 50% confluent Vero cells using Lipofectamine (GIBCO-BRL, Gaithersburg, MD) according to
the manufacturer’s instructions. Twenty-four hours post
transfection (h p.t.), the cells were infected at an m.o.i. of
10 with d27–1 virus (ICP27-null) as described previously
for the generation of the gK null virus, DgK (Jayachandra
et al., 1997). At 48 h p.i., the cells were freeze-thawed
three times, and the resultant virus stocks were plated
onto Vero cells and overlaid with agarose. Virus plaques
were visualized by fluorescent microscopy, individual
virus plaques were isolated, and virus was plaque purified five times on Vero cells.
Diagnostic PCR
Primer pairs UL52KpnI2/gKTr2, and UL52KpnI2/CMVBamHI were used to confirm the EGFP gene insertion as
described previously (Foster et al., 1999). Primer pair
UL52KpnI2/d27–1a was used to detect the presence of
contaminating d27–1 viral DNA. Reaction conditions for
UL52KpnI2/gKTr2 and UL52KpnI2/d27–1a pairs were
98°C for 3 s and 72°C for 7 min, repeated for 30 cycles
using rTth XL-Polymerase (Perkin–Elmer, Inc.). Reaction
conditions for the UL52KpnI2/CMVBamHI primer pair
were 98°C for 3 s and 72°C for 3 min, repeated for 30
cycles using rTth XL-Polymerase.
Construction of Chinese hamster ovary (CHO) cell
lines transformed with the HveAs or HveAs:Fc genes
Plasmid pCMV/HveAs, pCMV/sAevH, and pCR/HveAs:Fc
were transfected into CHO cells using LipofectAmine
and transformed cells were selected using Zeocin for the
first two plasmids (Invitrogen, Carlsbad, CA) and G418
(Sigma, Inc.) for the pCR/HveAs:Fc plasmid. Individual
CHO colonies were isolated, expanded, and tested for
the presence of the HveAs gene using PCR and Southern
blotting.

373

Plasmid pCMV/HveAs was used to generate mouse
anti-HveAs antibodies by direct injection into mice (genetic immunization). Purified plasmid DNA was inoculated intramuscularly into mice five times approximately
every 4 weeks. HveAs was expressed in E. coli as a
fusion protein with the maltose binding protein (MBP) by
plasmid pMAL/HveAs and purified according to the manufacturer’s instructions (NEB, Beverly, MA). Anti-HveAs
antibodies were tested in immunoblots against the MBP/
HveAs fusion protein essentially as described previously
(Foster et al., 1999).

HveAs:Fc protein secreted in supernatant fluids of ;10 7
CHO/HveAs:Fc-transformed cells was purified using protein A sepharose beads. Samples were resuspended in
SDS–PAGE sample buffer and electrophoretically separated in a 10% SDS–polyacrylamide gels. Following electrophoretic separation, proteins were electrotransferred
to nitrocellulose membranes. Blots were blocked against
nonspecific binding and incubated with horse radish
peroxidase conjugated goat anti-mouse secondary antibody (Pierce, Rockford, IL) at a 1:50,000 dilution in TBS-T.
Blots were visualized by autoradiography using the Pierce
SuperSignal chemiluminescent detection kit (Pierce) as
per the manufacturer’s instructions.
Phase-contrast and fluorescent microscopy
Subconfluent cell monolayers in 24-well plates were
infected with the KOS/EGFP virus at an m.o.i. of 0.02 for
visualization of individual viral plaques by either phase
contrast or fluorescence microscopy essentially as described previously for the DgK/EGFP virus (Foster et al.,
1999). Viral entry experiments were performed at m.o.i. of
10 and visualized by fluorescence microscopy at 24 h p.i.
FACS analysis
CHO-transformed cells expressing HveAs or Vero
cells were fixed with paraformaldehyde and incubated
with anti-HveAs antibody for 1 h at 4°C. Next cells were
washed three times with PBS buffer, incubated with
goat-anti-mouse FITC-conjugated secondary antibody
(Sigma, Inc.), and analyzed by FACS. KOS- and KOS/
EGFP-infected Vero cells were analyzed by FACS at 24 h
p.i. as described previously (Foster et al., 1999).
Inhibition of virus entry by anti-HveAs antibody and
soluble HveA-Fc protein
CHO/HveAs cells were incubated with either pre-immune or anti-HveAs serum for 1 h at room temperature
immediately prior to infection with KOS/EGFP at a m.o.i.
of 10. One milliliter of supernatant fluids from either
CHO/HveAs:Fc or CHO cells transformed with pCR3.1
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(control) was mixed with 1 ml of KOS/EGFP virus stock
(1 3 10 8 PFU/ml) and incubated at 4°C for 1 h immediately prior to infection. The amount of virus used in these
experiments was ;10 6 PFU per 10 5 CHO/HveAs cells.
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